Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel E Singer

Showing results (211-220 of 313) with videos related to

Pageof 32
Sort By:
American Heart Journal|September 29, 2014
Reasons for warfarin discontinuation in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)Emily C O'Brien, DaJuanicia N Simon, Larry A Allen, et al.
American Heart Journal|June 20, 2017
Factors associated with non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II)Benjamin A Steinberg, Peter Shrader, Laine Thomas, et al.
Journal of the American Heart Association|July 29, 2022
Natural Language Processing to Improve Prediction of Incident Atrial Fibrillation Using Electronic Health RecordsJeffrey M Ashburner, Yuchiao Chang, Xin Wang, et al.
Circulation|October 19, 2016
Influence of Kidney Function Estimation Methods on Eligibility for Edoxaban Population Impact of the US Food and Drug Administration's Approach for Its Product LabelingSean D Pokorney, Peter Shrader, Laine Thomas, et al.
Circulation|April 1, 2014
Lack of concordance between empirical scores and physician assessments of stroke and bleeding risk in atrial fibrillation: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registryBenjamin A Steinberg, Sunghee Kim, Laine Thomas, et al.
BMC Public Health|April 17, 2015
Comparative Effectiveness of Post-Discharge Strategies for Hospitalized Smokers: study protocol for the Helping HAND 2 randomized controlled trialZachary Z Reid, Susan Regan, Jennifer H K Kelley, et al.
Stroke|February 3, 2009
Effect of age on stroke prevention therapy in patients with atrial fibrillation: the atrial fibrillation investigatorsCarl van Walraven, Robert G Hart, Stuart Connolly, et al.
American Journal of Preventive Medicine|September 21, 2016
A Post-Discharge Smoking-Cessation Intervention for Hospital Patients: Helping Hand 2 Randomized Clinical TrialNancy A Rigotti, Hilary A Tindle, Susan Regan, et al.
European Heart Journal|August 30, 2011
Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairmentKeith A A Fox, Jonathan P Piccini, Daniel Wojdyla, et al.
Annals of Internal Medicine|November 14, 2017
Outcomes of Dabigatran and Warfarin for Atrial Fibrillation in Contemporary Practice: A Retrospective Cohort StudyAlan S Go, Daniel E Singer, Sengwee Toh, et al.
Pageof 32

Showing results (211-220 of 313) with videos related to

Sort By:
Pageof 32
American Heart Journal|September 29, 2014
Reasons for warfarin discontinuation in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)Emily C O'Brien, DaJuanicia N Simon, Larry A Allen, et al.
American Heart Journal|June 20, 2017
Factors associated with non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II)Benjamin A Steinberg, Peter Shrader, Laine Thomas, et al.
Journal of the American Heart Association|July 29, 2022
Natural Language Processing to Improve Prediction of Incident Atrial Fibrillation Using Electronic Health RecordsJeffrey M Ashburner, Yuchiao Chang, Xin Wang, et al.
Circulation|October 19, 2016
Influence of Kidney Function Estimation Methods on Eligibility for Edoxaban Population Impact of the US Food and Drug Administration's Approach for Its Product LabelingSean D Pokorney, Peter Shrader, Laine Thomas, et al.
Circulation|April 1, 2014
Lack of concordance between empirical scores and physician assessments of stroke and bleeding risk in atrial fibrillation: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registryBenjamin A Steinberg, Sunghee Kim, Laine Thomas, et al.
BMC Public Health|April 17, 2015
Comparative Effectiveness of Post-Discharge Strategies for Hospitalized Smokers: study protocol for the Helping HAND 2 randomized controlled trialZachary Z Reid, Susan Regan, Jennifer H K Kelley, et al.
Stroke|February 3, 2009
Effect of age on stroke prevention therapy in patients with atrial fibrillation: the atrial fibrillation investigatorsCarl van Walraven, Robert G Hart, Stuart Connolly, et al.
American Journal of Preventive Medicine|September 21, 2016
A Post-Discharge Smoking-Cessation Intervention for Hospital Patients: Helping Hand 2 Randomized Clinical TrialNancy A Rigotti, Hilary A Tindle, Susan Regan, et al.
European Heart Journal|August 30, 2011
Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairmentKeith A A Fox, Jonathan P Piccini, Daniel Wojdyla, et al.
Annals of Internal Medicine|November 14, 2017
Outcomes of Dabigatran and Warfarin for Atrial Fibrillation in Contemporary Practice: A Retrospective Cohort StudyAlan S Go, Daniel E Singer, Sengwee Toh, et al.
Pageof 32